- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)…
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)…
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted…
Founded by a team of physicians and AI experts, EasyPA launched the nation's first fully operational prior authorization (PA) platform…
Technology-enabled solution expands access to high-touch, personalized dementia care at home BOSTON, Aug. 12, 2025 /PRNewswire/ -- Neuroglee Health, a…
NEW YORK, NY / ACCESS Newswire / August 12, 2025 / Inc., the leading media brand and playbook for the…
BOSTON--(BUSINESS WIRE)--#histologymatters--Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive…
Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on…
TEMPE, Ariz., Aug. 7, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in July after one month of contraction, preceded…
New suite of tools, analysis, and data intelligence empowers healthcare and medical organizations to unlock competitive advantages and identify strategic…